Clinical Trial Update: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

View source ↗

Summary

Expanded access program update for emicizumab in participants with Hemophilia A with inhibitors, outlining current program status and access details.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Hemophilia A | Status: APPROVED_FOR_MARKETING